Results 101 to 110 of about 1,198,663 (392)

Cancer Cell Membrane-Coated Adjuvant Nanoparticles with Mannose Modification for Effective Anticancer Vaccination.

ACS Nano, 2018
Tumor vaccines for cancer prevention and treatment have attracted tremendous interests in the area of cancer immunotherapy in recent years. In this work, we present a strategy to construct cancer vaccines by encapsulating immune-adjuvant nanoparticles ...
Rong Yang, Jun Xu, Ligeng Xu, Xiaoqi Sun, Qian Chen, Yuhuan Zhao, Rui Peng, Zhuang Liu   +7 more
semanticscholar   +1 more source

Alum adjuvant: some of the tricks of the oldest adjuvant

Journal of Medical Microbiology, 2012
Alum has been the most widely used adjuvant for over 80 years. Although there have been searches for alternative adjuvants, aluminium-containing adjuvants will continue to be used for many years due to their good track record of safety, low cost and adjuvanticity with a variety of antigens.
Kaat Fierens, Mirjam Kool, Bart N. Lambrecht   +2 more
openaire   +4 more sources

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

Molecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed, Lucas Mani, Muhammad Bilal Mirza, Ashtyn McAdoo, Takahito Kondo, Hidenori Tanaka, Nicole Meeks, Eben Rosenthal, Marisa Hom   +8 more
wiley   +1 more source

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. [PDF]

, 2019
Glioblastoma is the most common primary malignant brain tumor in adults and is associated with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a randomized, multi-institution clinical trial to evaluate immune responses ...
Arrillaga-Romany, Isabel C, Butowski, Nicholas A, Clarke, Jennifer L, Cloughesy, Timothy F, Cohen, Adam L, Colman, Howard, Davidson, Tom B, de Groot, John F, Du, Lin, Ellingson, Benjamin M, Gaffey, Sarah C, Hugo, Willy, Kaley, Thomas J, Kawaguchi, Eric S, Lee, Alexander H, Lee, Eudocia Q, Li, Gang, Liau, Linda M, Mellinghoff, Ingo K, Mochizuki, Aaron Y, Nghiemphu, Phioanh L, O'Brien, Barbara J, Orpilla, Joey R, Prins, Robert M, Reardon, David A, Rytlewski, Julie A, Sanders, Catherine M, Wang, Anthony C, Wen, Patrick Y, Yong, William H   +29 more
core  

Zurich Consensus: German Expert Opinion on the St. Gallen Votes on 15 March 2009 (11th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer) [PDF]

, 2009
A German working group of 23 breast cancer experts discussed the results from the vote at this year's St. Gallen Consensus Conference on Primary Therapy for Early Breast Cancer ( March 11-14, 2009) and came up with some concrete recommendations for day ...
Beckmann, Matthias W., Blohmer, Jens-Uwe, Costa, Serban-Dan, Diedrich, Klaus, Diel, Ingo, Eiermann, Wolfgang, Friese, Klaus, Gerber, Bernd, Harbeck, Nadia, Hilfrich, Joern, Jaenicke, Fritz, Janni, Wolfgang, Jonat, Walter, Kaufmann, Manfred, Kiechle, Marion, Koehler, Uwe, Kreienberg, Rolf, Minckwitz, Gunter von, Moebus, Volker, Nitz, Ulrike, Schneeweiss, Andreas, Thomssen, Christoph, Wallwiener, Diethelm   +22 more
core   +2 more sources

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.

New England Journal of Medicine, 2007
BACKGROUND Advanced gastric cancer can respond to S-1, an oral fluoropyrimidine. We tested S-1 as adjuvant chemotherapy in patients with curatively resected gastric cancer.
S. Sakuramoto, M. Sasako, Toshiharu Yamaguchi, T. Kinoshitá, M. Fujii, A. Nashimoto, H. Furukawa, T. Nakajima, Y. Ohashi, H. Imamura, M. Higashino, Y. Yamamura, A. Kurita, K. Arai   +13 more
semanticscholar   +1 more source

Engineered immunogen binding to alum adjuvant enhances humoral immunity

Nature Network Boston, 2020
Adjuvants are central to the efficacy of subunit vaccines. Aluminum hydroxide (alum) is the most commonly used vaccine adjuvant, yet its adjuvanticity is often weak and mechanisms of triggering antibody responses remain poorly understood.
Tyson J. Moyer, Y. Kato, W. Abraham, Jason Y. H. Chang, Daniel W. Kulp, N. Watson, H. Turner, Sergey Menis, R. Abbott, Jinal Bhiman, M. Melo, Hayley Simon, S. Herrera-de la Mata, Shu Liang, G. Seumois, Yash Agarwal, Na Li, D. Burton, A. Ward, W. Schief, S. Crotty, D. Irvine   +21 more
semanticscholar   +1 more source

Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma

Molecular Oncology, EarlyView.
GA text Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...
Piotr J. Manasterski, Molly R. Danks, John P. Thomson, Morwenna Muir, Martin Lee, John C. Dawson, Ana T. Amaral, Juan Diaz‐Martin, David S. Moura, Javier Martin‐Broto, Ali Alsaadi, Donald M. Salter, Ailsa J. Oswald, Graeme Grimes, Larry Hayward, Ted R. Hupp, Karen Sisley, Paul H. Huang, Neil O. Carragher, Valerie G. Brunton   +19 more
wiley   +1 more source

The subcellular distribution of phosphorylated Y‐box‐binding protein‐1 at S102 in colorectal cancer patients, stratified by KRAS mutational status and clinicopathological features

Molecular Oncology, EarlyView.
This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...
Konstanze Lettau, Stephan Forchhammer, Birgit Fehrenbacher, Lejla Mahmutovic, Marcus Scharpf, Gunnar Blumenstock, Martin Schaller, Irina Bonzheim, Shayan Khozooei, Mahmoud Toulany   +9 more
wiley   +1 more source

Screening vaccine formulations for biological activity using fresh human whole blood. [PDF]

, 2014
Understanding the relevant biological activity of any pharmaceutical formulation destined for human use is crucial. For vaccine-based formulations, activity must reflect the expected immune response, while for non-vaccine therapeutic agents, such as ...
Aboutorabian, Sepideh, Ausar, Salvador F, Brookes, Roger H, Dockrell, Hazel M, Ha, Yukyung, Hakimi, Jalil, Hasija, Manvi, Rahman, Nausheen, Smith, Steven G, Todryk, Stephen M   +9 more
core   +1 more source